FindTrial
Sign In

Ahmed Glaucoma Valve Alone, With Amniotic Membrane or With Mitomycin C (MMC) for Treatment of Refractory Glaucoma

Ahmed Glaucoma Valve Alone,With Amniotic Membrane or With MMC for Treatment of Refractory Glaucoma

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00893490
Enrollment
Unknown
Registered
2009-05-06
Start date
Unknown
Completion date
Unknown
Last updated
2009-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Glaucoma

Brief summary

This randomized, controlled trial (RCT) compares the efficacy and safety of Ahmed Glaucoma Valve (AGV) implantation alone, with 3 minutes MMC application or with a single layer coverage of amniotic membrane. Outcomes include intraocular eye pressure (IOP), postoperative glaucoma medication and complications. AGV implantation site will be superior or inferior based on indication and these groups will be randomized separately.

Interventions

DEVICEAhmed Glaucoma Valve (AGV)

AGV implantation

DRUGMitomycin C (MMC)

3 minute MMC application

PROCEDUREamniotic membrane coverage

single layer coverage of amniotic membrane

Sponsors

Shahid Beheshti University of Medical Sciences
Lead SponsorOTHER

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
7 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* patients with refractory glaucoma

Exclusion criteria

* children under 7 years old * adults above 75 years old * uncooperative patients * patients underwent the operation for second time * patients with major operation with AGV

Countries

Iran

Contacts

Primary ContactShahin Yazdani, MD
shahinyazdani@yahoo.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026